Q1 2019 EPS Estimates for MEDNAX Inc (MD) Decreased by Analyst
MEDNAX Inc (NYSE:MD) – Leerink Swann dropped their Q1 2019 earnings estimates for shares of MEDNAX in a report released on Tuesday, December 4th. Leerink Swann analyst A. Gupte now expects that the company will post earnings per share of $0.86 for the quarter, down from their prior estimate of $0.91. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for MEDNAX’s Q2 2019 earnings at $1.01 EPS, Q3 2019 earnings at $1.09 EPS and Q4 2019 earnings at $1.09 EPS.
Several other equities analysts also recently commented on the company. ValuEngine downgraded MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 1st. Bank of America upgraded MEDNAX from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $60.00 to $50.00 in a research note on Tuesday, September 18th. Zacks Investment Research cut MEDNAX from a “hold” rating to a “sell” rating in a research note on Wednesday. UBS Group started coverage on MEDNAX in a research note on Friday, November 16th. They issued a “sell” rating and a $37.00 price target for the company. Finally, BMO Capital Markets decreased their price target on MEDNAX from $48.00 to $43.00 and set a “market perform” rating for the company in a research note on Friday, November 2nd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $51.20.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.97 by ($0.03). MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The business had revenue of $896.60 million during the quarter, compared to analysts’ expectations of $908.15 million. During the same period in the prior year, the firm posted $0.87 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis.
A number of hedge funds have recently modified their holdings of MD. BlackRock Inc. grew its holdings in shares of MEDNAX by 2.8% in the 3rd quarter. BlackRock Inc. now owns 8,352,351 shares of the company’s stock worth $389,720,000 after acquiring an additional 227,101 shares during the period. Vanguard Group Inc. increased its holdings in MEDNAX by 3.9% in the 3rd quarter. Vanguard Group Inc. now owns 8,282,555 shares of the company’s stock valued at $386,464,000 after purchasing an additional 314,415 shares in the last quarter. Pzena Investment Management LLC grew its stake in shares of MEDNAX by 41.5% during the third quarter. Pzena Investment Management LLC now owns 3,254,122 shares of the company’s stock valued at $151,837,000 after acquiring an additional 954,322 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of MEDNAX by 2.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,233,798 shares of the company’s stock valued at $104,226,000 after acquiring an additional 50,806 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of MEDNAX by 39.6% during the third quarter. Bank of New York Mellon Corp now owns 1,764,948 shares of the company’s stock valued at $82,353,000 after acquiring an additional 500,538 shares in the last quarter. Hedge funds and other institutional investors own 98.16% of the company’s stock.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.